MEDNAX reported a challenging first quarter, marked by a net revenue of $846 million but a loss of $16 million. The company's performance was significantly impacted by the COVID-19 pandemic, which reduced consolidated revenue by approximately $40 million compared to forecasted revenue. Additionally, MEDNAX completed the sale of American Anesthesiology subsequent to the end of the quarter.
Net revenue for the quarter was $846 million.
Loss from continuing operations was $16 million, or $0.20 per share.
Adjusted EPS from continuing operations was $0.32.
Adjusted EBITDA from continuing operations was $63 million.
Due to the rapidly evolving environment and continued uncertainties surrounding the impact of COVID-19, the Company is not providing any outlook for its performance for the second quarter of 2020 or for the full year 2020.
Analyze how earnings announcements historically affect stock price performance